Who
Brigette Roberts
Chief Corp. Affairs Officer
Company insider
Files Form 4 as: Chief Corp. Affairs Officer, Quince Therapeutics; Director, Ligand Pharmaceuticals.
In numbers
- Trades disclosed
- 20
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 4 Jan 2006
- Last trade
- 18 May 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,675 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —228,855 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —124,830 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,675 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —228,855 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —124,830 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —69,350 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —362,092 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —133,615 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,070,107 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,837,319 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,837,319 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —69,350 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —362,092 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —133,615 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,070,107 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,837,319 | filing |
| 18 May 2026filed 11 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,837,319 | filing |
| 3 Jan 2007filed 5 Jan 2007 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,781 | filing |
| 4 Jan 2006filed 6 Jan 2006 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $27K2,378 at $11.56 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.